Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2026
Novo's Ozempic to gain insurance coverage for diabetes in Korea from February under new criteria
23 January 2026 - Starting in February, Korea's national health insurance will cover Novo Nordisk's Ozempic pre-filled pen, which contains ...
Posted by Michael Wonder on 21 Jan 2026
Truqap faces double barrier in Korea as NGS and drug reimbursement lag
20 January 2026 - As demand for next generation sequencing screening rises, a new drug for metastatic breast cancer faces ...
Posted by Michael Wonder on 18 Jan 2026
Darzalex clears HIRA hurdle for AL amyloidosis reimbursement in Korea
16 January 2026 - The treatment barriers will likely be significantly lowered for patients with rare diseases in Korea, such ...
Posted by Michael Wonder on 07 Jan 2026
Korea’s next homegrown drug could be a first local CAR-T as payer keeps widening access
6 January 2026 - Korea spent 2025 doing something it has not always been quick to do: it paid for ...
Posted by Michael Wonder on 04 Jan 2026
Bayer Korea's Eylea pre-filled syringe 8 mg to receive health insurance coverage
30 December 2025 - Bayer Korea announced that its Eylea pre-filled syringe 8 mg will be covered by health insurance ...
Posted by Michael Wonder on 04 Jan 2026
GC Biopharma’s Livmarli listed for national health insurance coverage for Alagille syndrome
2 January 2026 - GC Biopharma said Livmarli (maralixibat chloride), a treatment for Alagille syndrome, has been officially listed on ...
Posted by Michael Wonder on 28 Dec 2025
Drug makers push back against government’s generic price cut plan
28 December 2025 - Pharma industry warns lower generic prices will curb R&D, health officials cite unchanged pricing since 2012. ...
Posted by Michael Wonder on 25 Dec 2025
Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026
24 December 2025 - Korea’s national health insurance program will broaden reimbursement for MSD’s blockbuster PD-1 inhibitor Keytruda in a ...
Posted by Michael Wonder on 24 Dec 2025
Pharma industry pushes back against generic drug price cuts
23 December 2025 - South Korea's pharmaceutical and biotech industry has begun mounting a coordinated backlash against the government's plan ...
Posted by Michael Wonder on 24 Dec 2025
Lilly’s Jaypirca wins Korea reimbursement for relapsed mantle cell lymphoma
10 October 2025 - Eli Lilly’s Jaypirca (pirtobrutinib) has been added to Korea’s national health insurance effective Oct. 1 for ...
Posted by Michael Wonder on 24 Dec 2025
Korea pharma groups warn price reform will cut 3.6 trillion won and cost jobs
22 December 2025 - Pharma associations form emergency committee to demand delay and joint review of planned generic price cuts. ...
Posted by Michael Wonder on 02 Dec 2025
Korea eases path to breakthrough drugs with flexible ICER rules
1 December 2025 - The Government has unveiled a large-scale overhaul of the health insurance drug pricing system, proposing flexible ...
Posted by Michael Wonder on 02 Dec 2025
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to first-line therapy
1 December 2025 - GSK’s Jemperli has secured its position as a standard treatment option in endometrial cancer following Korea’s ...
Posted by Michael Wonder on 30 Nov 2025
Korea launches sweeping drug pricing reform to curb generic dominance
29 November 2025 - The Government will launch a large scale overhaul of the drug pricing system starting in the ...
Posted by Michael Wonder on 12 Nov 2025
AstraZeneca’s Imfinzi, Imjudo, and Ultomiris clear reimbursement panel review
7 November 2025 - AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab), the anti-CTLA-4 immune checkpoint inhibitor Imjudo (tremelimumab), and the ...